Why the study?
Does anticoagulation with edoxaban reduce cardiovascular death, stroke, or systemic embolism in patients with atrial high-rate episodes detected by implantable devices?
Does anticoagulation with edoxaban reduce cardiovascular death, stroke, or systemic embolism in patients with atrial high-rate episodes detected by implantable devices?
In patients with device-detected atrial high-rate episodes, routine anticoagulation with edoxaban did not reduce thromboembolic events but significantly increased the risk of major bleeding or death.
No takes yet. Share an insight, caveat, or question.
Edoxaban should not be used routinely for device-detected AHREs; challenges assumptions favoring anticoagulation in subclinical atrial tachyarrhythmias.
Kirchhof et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: